Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $103 | $136 | $61 | $51 |
| Short-Term Investments | $220 | $278 | $372 | $435 |
| Receivables | $32 | $30 | $29 | $27 |
| Inventory | $3 | $6 | $6 | $0 |
| Other Curr. Assets | $27 | $21 | $22 | $22 |
| Total Curr. Assets | $383 | $471 | $490 | $540 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $9 | $13 | $13 | $13 |
| Total NC Assets | $10 | $14 | $14 | $14 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $393 | $485 | $504 | $554 |
| Liabilities | – | – | – | – |
| Payables | $10 | $0 | $13 | $14 |
| Short-Term Debt | $0 | $110 | $110 | $110 |
| Tax Payable | $3 | $2 | $3 | $3 |
| Deferred Revenue | $0 | -$0 | $0 | $0 |
| Other Curr. Liab. | $81 | $77 | $85 | $106 |
| Total Curr. Liab. | $91 | $187 | $207 | $230 |
| LT Debt | $224 | $224 | $223 | $223 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $7 | $6 | $6 | $7 |
| Total NC Liab. | $230 | $230 | $230 | $231 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $321 | $417 | $437 | $461 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,178 | -$2,175 | -$2,169 | -$2,137 |
| AOCI | -$7 | -$8 | -$8 | -$8 |
| Other Equity | $2,257 | $2,250 | $2,244 | $2,238 |
| Total Equity | $72 | $68 | $67 | $93 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $393 | $485 | $504 | $554 |
| Net Debt | $121 | $197 | $272 | $282 |